| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
109,470,000 |
| Market
Cap: |
111.66(M) |
| Last
Volume: |
627,989 |
Avg
Vol: |
626,253 |
| 52
Week Range: |
$0.5601 - $1.41 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vaxart is a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology proprietary oral vaccine platform. Co.'s oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Co.'s investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. In addition, Co. is in early development of its first therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
25,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$31,240 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Berg Edward B |
SVP, General Counsel |
• • – |
2023-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
187,606 |
187,606 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2023-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
189,157 |
316,788 |
|
- |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2023-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
191,652 |
260,402 |
|
- |
|
| Watson W. Mark |
Director |
• • – |
2022-12-28 |
4 |
B |
$0.76 |
$15,140 |
D/D |
20,000 |
20,000 |
2.39 |
12% |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
68,750 |
68,750 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2022-08-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,894 |
|
-71% |
|
| Heron Elaine J |
Director |
• • – |
2022-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
14,750 |
17,644 |
|
- |
|
| Yedid Robert A. |
Director |
• • – |
2022-08-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
26,240 |
11,115 |
|
- |
|
| Yedid Robert A. |
Director |
• • – |
2022-08-19 |
4 |
OE |
$0.31 |
$24,774 |
D/D |
26,240 |
37,355 |
|
- |
|
| Wheadon David E. |
Director |
• • – |
2022-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
7,375 |
7,375 |
|
- |
|
| Cherrington Julie M |
Director |
• • – |
2022-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
6,217 |
6,217 |
|
- |
|
| Finney Michael J. |
Director |
• • – |
2022-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
7,375 |
663,465 |
|
- |
|
| Watson W. Mark |
Director |
• • – |
2022-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
14,750 |
14,750 |
|
- |
|
| Yedid Robert A. |
Director |
• • – |
2022-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
7,375 |
11,115 |
|
- |
|
| Davis Todd C |
Director |
• • – |
2022-08-04 |
4 |
A |
$0.00 |
$0 |
D/D |
7,375 |
125,905 |
|
- |
|
| Ahmad Fuad |
Interim CFO |
• • – |
2022-06-22 |
4 |
B |
$3.22 |
$16,100 |
D/D |
5,000 |
5,000 |
2.74 |
-53% |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2022-04-22 |
4 |
OE |
$0.77 |
$30,800 |
D/D |
40,000 |
127,631 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2022-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
87,631 |
|
- |
|
| Floroiu Cezar Andrei |
President, Chief Exec Officer |
• • – |
2022-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
85,000 |
|
- |
|
| Cummings James F. |
Chief Medical Officer |
• • – |
2022-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
43,750 |
43,750 |
|
- |
|
| Yedid Robert A. |
Director |
• • – |
2022-01-10 |
4 |
S |
$6.01 |
$9,015 |
I/I |
(1,500) |
0 |
|
43% |
|
| Davis Todd C |
Director |
• • – |
2021-12-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,470 |
118,530 |
|
- |
|
| Yedid Robert A. |
Director |
• • – |
2021-10-12 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,500 |
1,500 |
|
- |
|
| Yedid Robert A. |
Director |
• • – |
2021-10-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,500 |
3,740 |
|
- |
|
| Echerd Margaret |
SVP, Principal Accntng Officer |
• • – |
2021-09-10 |
4 |
AS |
$9.10 |
$16,389 |
D/D |
(1,801) |
0 |
|
-45% |
|
187 Records found
|
|
Page 2 of 8 |
|
|
0.08 (7.98%) 
